title: [Idiopathic sudden sensorineural hearing loss. What's the appropriate management?].
abstract: BACKGROUND
  Sudden sensorineural hearing loss remains a challenge in otology. Controverses affect mainly etiopathogeny and treatment.
  
  
  OBJECTIVE
  To evaluate our experience in the diagnosis and the treatment of sudden hearing loss
  
  
  METHODS
  We report a retrospective study, including 30 patients presenting a Sudden sensorineural hearing loss. All patients were hospitalized for treatment. The audiometry evaluated the hearing deafness before and after treatment.
  
  
  RESULTS
  The average age was of 48 years. In all the cases no etiology has been found. All The patients were hospitalized and corticotherapy was administrated in all cases. It was associated to hyperbare oxygenotherapy in 7 patients. Recovery was observed mainly in patients with moderate (71.4%) and severe hearing deficiency (69.2%).
  
  
  CONCLUSIONS
  Corticosteroids are the less controversed treatment of sudden sensorineural hearing loss.
authors.affiliation: Service ORL & Chirurgie Cervico-Faciale, Hôpital Habib Thameur Tunis, Tunisie.
authors.forename: Olfa
authors.initials: O
authors.lastname: Ben Gamra
authors.forename: Chiraz
authors.initials: C
authors.lastname: Mbarek
authors.forename: Imen
authors.initials: I
authors.lastname: Ben Rejab
authors.forename: Ines
authors.initials: I
authors.lastname: Hariga
authors.forename: Hajer
authors.initials: H
authors.lastname: Bhar
authors.forename: Lamia
authors.initials: L
authors.lastname: Sghaier
authors.forename: S
authors.initials: S
authors.lastname: Zribi
authors.forename: A
authors.initials: A
authors.lastname: El Khedim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006309:Hearing / Q000502:physiology; D003639:Hearing Loss, Sudden / Q000175:diagnosis / Q000628:therapy*; D006760:Hospitalization; D006801:Humans; D006931:Hyperbaric Oxygenation; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020127:Recovery of Function / Q000502:physiology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D009257:Nafronyl; D001241:Aspirin; D010431:Pentoxifylline; D008775:Methylprednisolone